Friday, October 23, 2009
Exelixis, Bristol-Myers' Brain Cancer Drug Show Activity In Phase II Study ... - RTT News
Exelixis, Bristol-Myers' Brain Cancer Drug Show Activity In Phase II Study ...
RTT News
BMY last traded at $22.24, down 0.98% or 22 cents in Friday's regular trade, on the NYSE. In after-hours trading, BMY lost 12 cents. by RTT Staff Writer.
and more »
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment